CA
PBYI icon

Crewe Advisors’s Puma Biotechnology PBYI Stock Holding History

Crewe Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-579
Closed -$2.45K – 985
2022
Q4 		$2.45K Hold
579
– – ﹤0.01% 808
2022
Q3 		$1K Hold
579
– – ﹤0.01% 1178
2022
Q2 		$2K Buy
+579
New +$1.44K ﹤0.01% 996

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return

Crewe Advisors's PBYI Position: Q1 2023 in Review

Crewe Advisors sold out of Puma Biotechnology (PBYI) in Q1 2023, closing a stake of 579 shares — an estimated $2.45K sold.

Crewe Advisors first reported a position in PBYI in Q2 2022 and held it in 3 quarters. The position peaked at $2.45K in Q4 2022. 77 funds tracked by Wall St. Rank hold PBYI as of Q1 2023.

  • Crewe Advisors reported no remaining Puma Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Crewe Advisors sold 579 Puma Biotechnology shares in Q1 2023, an estimated $2.45K.
  • Crewe Advisors first reported a position in Puma Biotechnology in Q2 2022 and held it in 3 quarters.
  • Crewe Advisors's Puma Biotechnology position peaked at $2.45K in Q4 2022.
  • 77 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2023.

Based on Crewe Advisors's 13F filing for Q1 2023, filed 12 May 2023.